Pay in 4 interest-free payments of $5.06 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
doi:10.1111/1750-3841.14952
Hyperbaric Oxygen Therapy Indications, 14th Edn
J Biol Chem (2006) 281(45):3412434
Research applications In-vitro modeling of synergistic GHRH/GHRP receptor cross-talk Pre-clinical study of pulsatile GH-secretagogue dynamics Comparative receptor-pathway research (cAMP vs calcium convergence) Reference standard for analytical characterization of blended preparations Key facts Combines a GHRH-receptor analog with a selective GHS-R1a agonist Nominal 5mg + 5mg per-component loading per vial Components act through mechanistically independent, convergent pathways Supplied as a co-lyophilized research powder for in-vitro use Product specifications Class: GHRH analog + GHRP/ghrelin-receptor agonist research blend Also known as: Mod-GRF + Ipamorelin blend Form: Lyophilized powder vial Purity: 99% (HPLC verified) Testing: Independent third-party HPLC + mass spectrometry Documentation: Certificate of analysis per batch Storage: Store lyophilized at -20C
Semaglutide may harm your unborn baby
Cycling peptides periodically versus stopping completely can help maintain muscle gains and fat loss
